Titlebook: Combination Cancer Therapy; Modulators and Poten Gary K. Schwartz Book 2005 Humana Press 2005 Chemotherapie.apoptosis.carcinoma.cell.leukem

Genetics

,Targeted α-Particle Therapy,mab (Rituxan; IDEC Pharmaceuticals, San Diego, CA, and Genentech, Inc., South San Francisco, CA), trastuzumab (Herceptin; Genentech, Inc., South San Francisco, CA), and alemtuzumab (Campath-1H; Burroughs Wellcome, United Kingdom)—have been approved by the US Food and Drug Administration (FDA) for th

leniency

Pharmacological Modulation of Fluoropyrimidines,ornerstone of present-day developmental chemotherapy. From its rational synthesis by Heidelberger in 1957 (.) to quantification of the molecular determinants of fluorinated pyrimidine (fluoropyrimidine) activity, our understanding of fluoropyrimidine pharmacology has helped mold our concepts of ever

ENDOW

Development of Inhibitors of HER2 With Taxanes,ically treatable but not curable, the primary goal of clinical management is often to create an optimal equilibrium between maximizing response, minimizing toxicity, improving survival, and optimizing symptom palliation. The search for new drugs that might provide these characteristics, together wit

Transfusion

,Targeting NF-κB to Increase the Activity of Cisplatin in Solid Tumors,ment of resistance impacts the utility of the drug in many patients, particularly in the setting of recurrent disease. Although the exact mechanism of cisplatin resistance needs to be delineated, it is widely accepted that multiple factors may contribute to cisplatin resistance.

渗透

按时间顺序

Use of Animal Models to Evaluate Signal Transduction Inhibitors As Modulators of Cytotoxic Therapy, and respond to in “programmed” patterns (.). As the understanding of cancer has increased, the complexity of the molecular events that comprise malignant disease has become evident (.). Interactions involved in intertwining signaling networks including membrane receptors, enzymes along with activat

Harness

2196-9906 erapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cyc

前面

Recrystallization and Sintering in Ceramicsr novel targets and intervention combinations for the prevention and treatment of cancer. The advent of combination carboplatin/paclitaxel for the adjuvant treatment of ovarian cancer has led to improved response rates and prolonged survival (.). However, over 60% of patients relapse, and the 5-yr survival rate is still below 50%.

NAG

FRONT

Book 2005future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (